Boston Partners
CTKB icon

Boston Partners’s Cytek Biosciences CTKB Stock Holding History

Boston Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.9M Buy
7,660,943
+1,858,170
+32% +$7.93M 0.03% 324
2026
Q1 		$25.4M Buy
5,802,773
+794,464
+16% +$3.75M 0.03% 345
2025
Q4 		$25.3M Buy
5,008,309
+4,971,126
+13,369% +$23.1M 0.03% 351
2025
Q3 		$129K Buy
+37,183
New +$140K ﹤0.01% 752

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Boston Partners's CTKB Position: Q2 2026 in Review

Boston Partners increased its Cytek Biosciences (CTKB) stake by 32% in Q2 2026, buying an estimated $7.93M and bringing the position to 7,660,943 shares worth $33.9M. The position accounts for 0.03% of the portfolio, ranked #324.

Boston Partners first reported a position in CTKB in Q3 2025 and has held it in 4 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Boston Partners held 7,660,943 shares of Cytek Biosciences worth $33.9M as of Q2 2026.
  • Boston Partners bought 1,858,170 Cytek Biosciences shares in Q2 2026, an estimated $7.93M.
  • Cytek Biosciences made up 0.03% of Boston Partners's portfolio in Q2 2026, its #324 holding.
  • Boston Partners first reported a position in Cytek Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.